key: cord-0689630-wzb5qi56
authors: Benotmane, Ilies; Bruel, Timothée; Planas, Delphine; Fafi-Kremer, Samira; Schwartz, Olivier; Caillard, Sophie
title: A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients
date: 2022-02-26
journal: Kidney Int
DOI: 10.1016/j.kint.2022.02.011
sha: 867031388784ffc2d2d8974eaadf87a6b5781289
doc_id: 689630
cord_uid: wzb5qi56

nan

Research has suggested that even three doses of SARS-CoV-2 mRNA-based vaccines might be unable to elicit a sufficient immune response in immunocompromised kidney transplant recipients. 1, 2 While the antibody response mounted by the Pfizer and AstraZeneca vaccines in immunocompetent subjects seems sufficient to neutralize the delta variant, 3 the effectiveness appears three-to five-fold lower than that observed against the alpha variant. 4, 5 In addition, standard vaccination schemes are beset by low immunogenicity in immunocompromised subjectswho remain prone to develop severe COVID-19. 3 The purpose of this study is to describe the kinetics of the neutralizing antibody response against the delta strain before and after a fourth dose of the mRNA-1273 (Moderna) vaccine in kidney transplant recipients who had experienced a weak antibody response after three previous doses. We also assessed the correlation between this neutralizing activity and levels of IgG against the receptor binding domain (RBD) of the spike (S) protein. Figure 1A ). In parallel, median inhibitory dilution 50 (ID50) titers increased significantly (p=0.0001) from <7.5 (IQR : <7.5−15.1) to 47.1 (IQR <7.5−284.2).

While only 16% of patients (n = 11) harbored neutralizing antibodies against the delta strain prior to the fourth injection, this percentage raised to 66% (n = 44) afterwards ( Figure 1B ).

Patients with undetectable neutralizing antibodies after the third dose were less likely to have their neutralizing capacity increased after the fourth dose (median fold-change: 1.1 versus 6.3, p=0.01). Of the nine patients who were seronegative after the third dose, only one displayed a strong anti-RBD IgG response (>143 BAUs/mL) and two were able to neutralize the delta variant after the fourth dose. Additionally, 81% of patients with a weak immune response after the third dose displayed a strong anti-RBD IgG response after the fourth injection.

Notably, 63.8% of them were able to neutralize the delta variant after the fourth dose.

Interestingly, patients under combined therapy with tacrolimus, mycophenolate mofetil, and steroids displayed lower neutralizing ID50 titers (median ID50 titers: 25.6 versus 140.6, p=0.01). Neutralizing ID50 titers against the delta variant were positively correlated with anti-RBD titers (Pearson's r²=0.54, p<0.0001, Figure 1C ). Once the anti-RBD titer exceeded 143 BAUs/mL after the fourth dose, the specificity, sensitivity, positive predictive value, and negative predictive value to detect neutralizing activity were 92.9%, 74.3%, 93.6%, and 72.2% respectively. Neither major adverse events nor graft rejections were observed after the fourth dose. One patientwho lacked neutralizing activity after the fourth injection (ID50 titer: <7.5)developed symptomatic COVID-19 caused by the delta variant nineteen days after receiving the fourth dose.

In this cohort of 67 kidney transplant recipients who showed a low immune response after three doses of the mRNA-1273 (Moderna) vaccine, a fourth dose significantly increased the J o u r n a l P r e -p r o o f neutralizing response against the delta variant. Specifically, the proportion of patients harboring neutralizing antibodies against the delta strain rose significantly from 16% to 66%.

In our study, men displayed higher neutralizing ID50 titers than women. While this observation has no obvious pathophysiological explanations, it is in accordance with the results published by Masset et al. 6 after the third dose. Patients with a history of cellular or antibody-mediated rejection were less likely to display a neutralizing antibody response. This may be attributed to a higher burden of immunosuppression implemented in response to the rejection episodes. Only two published studies have focused on the effect of a fourth vaccine dose in patients who had undergone solid organ transplantation. In a small cohort of 18 solid organ transplant recipients, Alejo et al. 7 found that eight patients with negative or low response after the third dose developed high antibody titers after the fourth injectiona result in line with our current data. 7 Moreover, six of the ten patients who already had high positive titers after three doses showed additional boosting after the fourth injection. This report did not provide data on the neutralizing activitywhich has been shown to be highly predictive of immune protection against symptomatic SARS-CoV-2 infection. 8 In another cohort of 37 patients, Kamar et al. 9 assessed antibody response, neutralizing activity, and T cell response; a slight improvement of humoral response was observed. In the work by Kamar et al., 9 86% of the study patients (32 out of 37) had no immune response after three doses. Conversely, 87% of our study participants (58 out of 67) showed a weak antibody response after three doses. This may at least in part explain the discrepancies between the two investigations. This is, to our knowledge, the first study to assess the effect of a fourth dose vaccine by taking 

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Randomized Trial of a Third Dose of mRNA-1273

How do vaccinated people spread Delta? What the science says

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response

Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Assessment of 4 Doses of SARS-CoV-2

Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant